Effectiveness, Safety and Predictors of Response to Vedolizumab As First- or Second-Line Biological Therapy in Patients with Ulcerative Colitis: A Real-World Observational Multicenter Study.

S. Ferreira,R. Serafim Parra,L. Yukie Sassaki, J. M. Luz Parente, M. Kurtz de Mello, L. Andrade Chebli, R. L. Luporini, A. J. Tiburcio Alves Junior, F. J. Firmino Nobrega, B. C. da Silva,E. F. Miranda, A. Botelho Quaresma, G. Mattioli Nicollelli,R. Galhardi Gasparini, R. de Medeiros Dutra, K. da Conceicao da Silva, D. Oliveira Magro, M. R. Imbrizi, C. Kibune Nagasako,O. Feres, L. E. de Almeida Troncon,P. G. Kotze, J. M. Fonseca Chebli

JOURNAL OF CROHNS & COLITIS（2025）

Cited 0|Views2

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined